Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months
BURLINGTON, Mass., August 12, 2026 Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BURLINGTON, Mass., August 12, 2026 Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life...
STAMFORD, Connecticut, June 30, 2026 Gainline Capital Partners has announced that its portfolio company M&M International, a leading manufacturer...
SEATTLE, June 30, 2026 AGC Biologics has announced a strategic partnership with Pyramid Pharma Services to expand its U.S.-based...
INCHEON, South Korea & ROCKVILLE, Maryland, USA — March 31, 2026 Samsung Biologics has officially completed the acquisition of...
Brussels, Belgium & Atlanta, Georgia – March 24, 2026 Strategic Biologics Expansion to Strengthen Global Supply In a major...
Parsippany, New Jersey, USA | March 19, 2026 Embecta Corp. has announced a definitive agreement to acquire Owen Mumford...
CAMBRIDGE, England & BOSTON — December 16, 2025 — Bicycle Therapeutics plc, a clinical-stage pharmaceutical company pioneering bicyclic peptide–based...
MENLO PARK, CA — November 20, 2025 — Antheia announced a strategic partnership with TAPI (Teva Active Pharmaceutical Ingredients)...
WAUKESHA, WI – November 11, 2025 — Lifeway Foods, Inc. (NASDAQ: LWAY), a leading U.S. supplier of kefir and...
OTTAWA, Oct. 2, 2025 — Kinaxis announced that Sobi, a specialist in rare‐disease biopharma, will adopt the Kinaxis Maestro®...
